Drugs / Human Menopausal Gonadotrophins
Human Menopausal Gonadotrophins
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| — | NCT03684824 Background | Sep 2018 → Sep 2019 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT00492934 Comparator | Jan 2004 → Oct 2013 | infertility disorder | University Hospital, Gasthuisberg | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human menopausal gonadotrophins | “Controlled ovarian hyperstimulation will be done using daily intramuscular injection of highly purified Human Menopausal Gonadotrophins (Merional 75 IU/ml, IBSA, Switzerland),...” NCT03684824 ↗ |
| Known as | hMG | “cycle hormonally stimulated with s.c. gonadotrophins (hMG FET group, 37.5-75 IU per day, n = 288).” PMID 26364081 ↗ Sep 2015 |
| Known as | Human menopausal gonadotrophin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108951 ↗ |
| Route | Subcutaneous | “Daily subcutaneous injections, dose 37.5 IU or 75 IU, start on day 2 of the menstrual cycle until ovulation” NCT00492934 ↗ |